Times of crisis overwhelmingly bring out the good in society, however they also see the fakes and counterfitters crawl out from their shadowy world. With huge potential profits to be gained in the relatively short time that people are panicking there really is no better time to be extra cautious across our industry.

At QUINTA-ANALYTICA we take quality seriously not just in these unprecedented times, but ALL the time.  Quinta’s CCO Jiri Raska, explains “despite not being drug manufacturers per se, we’ve got our partners covered in all aspects of the services we provide to them, and we pride ourselves in the integrity of our end-to-end operations”.

The European Medicines Agency guidelines explain how checking the label, especially when buying online, is key to staying one step ahead, and this helpful post from the EFPIA – European Federation of Pharmaceutical Industries and Associations  goes further to breakdown the risk.

Additional News

  • 16 April 2026

    Expanding Beyond FDA & EMA: Strengthening Our Global Regulatory Footprint with GCC

    Quinta-Analytica has successfully completed a full on-site GCP inspection within the GCC framework, further strengthening its international regulatory footprint and clinical research credibility.

  • 25 March 2026

    ADC Webinar: DAR, Bioanalysis and Intact MS in Next-Generation ADC Development

    On behalf of Conscio Group, registration is now open for our free expert-led webinar on DAR characterization, bioanalytical strategy and mass spectrometry insight in ADC development.

  • 17 December 2025

    PF 2026: Thank You from Quinta-Analytica

    In 2025, Quinta-Analytica continued to turn complex development challenges into tangible progress. Our PF 2026 message looks back at key milestones and thanks the partners, clients, and teams who made them possible.